The renin-angiotensin system and vascular hypertrophy

Journal of the American College of Cardiology

Volumn 28, Issue 4, 1996, Pages 803-812

  Rosendorff, Clive ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDROIMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; BASIC FIBROBLAST GROWTH FACTOR; CALCIUM CHANNEL BLOCKING AGENT; DIACYLGLYCEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GUANINE NUCLEOTIDE BINDING PROTEIN; INOSITOL TRISPHOSPHATE; LOSARTAN; LOSARTAN POTASSIUM; MYC PROTEIN; PHOSPHOLIPASE C; PLATELET DERIVED GROWTH FACTOR A; PROTEIN C FOS; RECEPTOR SUBTYPE; TRANSFORMING GROWTH FACTOR BETA1;

ARTERIAL PRESSURE; ARTICLE; CELL DIVISION; CELL GROWTH; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPERPLASIA; MUSCLE HYPERTROPHY; ONCOGENE; PATHOPHYSIOLOGY; POLYPLOIDY; PRIORITY JOURNAL; RENIN ANGIOTENSIN DISORDER; RESISTANCE BLOOD VESSEL;

EID: 0030273707     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(96)00251-3     Document Type: Review

References (131)

1. Dzau VJ, Burt DW, Pratt RE. Molecular biology of the renin-angiotensin system. Am J Physiol 1988;255:F563-73.
2. Inagami T, Mizuno K, Nakamaru M, et al. The renin-angiotensin system: and overview of its intracellular function. Cardiovasc Drugs Ther 1988;2:453-8.
3. Gibbons GH, Dzau VJ. Angiotensin converting enzyme inhibition and vascular hypertrophy in hypertension. Cardiovasc Drugs Ther 1990;4:237-42.
4. Krieger JE, Dzau VJ Molecular biology of hypertension. Hypertension. 18(Suppl I):1991;I-3-17.
5. Dzau VJ. Vascular renin-angiotensin system and vascular protection. J Cardiovasc Pharmacol 1993;22 Suppl 5:S1-9.
6. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation 1993;87:1816-28.
7. Magrini F, Reggiani P, Roberts N, Meazza R, Ciulla M, Zanchetti A Effects of angiotensin and angiotensin blockade on coronary circulation and coronary reserve. Am J Med. 84(Suppl 3A):1988;55-60.
8. Samani NJ, Swales JD. Molecular biology of the vascular renin-angiotensin system. Blood Vessels 1991;28:210-6.
9. Ekker M, Tronik D, Rougeon R. Extrarenal transcription of the renin genes in multiple tissues of mice and rats. Proc Natl Acad Sci USA 1989;86:5155-8.
10. Rosendorff C, Knapp C The role of autocoids in the pathogenesis of cough induced by angiotensin converting enzyme inhibitors. Cardiology. 82(Suppl 2):1993;66-71.
11. Clozel M, Kuhn H, Hefti F. Effects of angiotensin converting enzyme inhibitor and of hydralazine on endothelial function in hypertensive rats. Hypertension 1990;16:532-40.
12. McGiff JC, Terragano NA, Malik KU, Lonigro AJ Release of a prostaglandin E-like substance from canine kidney by bradykinin. Circ Res. 31:1972;36-43.
13. Boulanger C, Schini VB, Moncada S, Vanhoutte PM. Release of EDRF and exogenous nitric oxide stimulate the production of cyclic AMP in cultured endothelial cells. Br J Pharmacol 1990;101:152-6.
14. Desta B, Vanhoutte PM, Boulanger CM. Inhibition of the angiotensin converting enzyme by perindoprilat and release of nitric oxide. Am J Hypertens 1995;8:S1-6.
15. Okamura R, Myazaki M, Inagami T, Toda N. Vascular renin angiotensin system in two kidney, one clip hypertensive rats. Hypertension 1986;8:560-5.
16. Morishita R, Higaki J, Okunkishi H, et al. Changes in gene expression of the renin angiotensin system in two kidney, one clip hypertensive rats. J Hypertens 1991;9:187-92.
17. Jandeleit K, Perich R, Jackson B, Johnston CI. Mesenteric resistance and brain microvascular angiotensin converting enzyme in the spontaneously hypertensive rat. Clin Exp Pharmacol Physiol 1992;19:348-52.
18. Perich R, Jackson B, Paxton D, Johnston CI. Characterization of angiotensin converting enzyme in isolated cerebral microvessels from spontaneously hypertensive and normotensive rats. J Hypertens 1992;101:149-53.
19. Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens 1993;11 Suppl 3:S13-8.
20. Phillips MI, Speakman EA, Kimura B Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept. 43:1993;1-20.
21. Klickstein LB, Kaempfer CE, Wintraub BU. The granulocyte-angiotensin system. Angiotensin I-converting activity of cathepsin G. J Biol Chem 1982;257:15042-6.
22. Tang SS, Loscalzo J, Dzau VJ Tissue plasminogen activator activates renin angiotensin in vitro. J Vasc Med Biol. 1:1989;67-74.
23. Okunishi H, Miyazaki M, Okamura T, Toda N. Different distributions of two types of angiotensin II generating enzymes in the aortic wall. Biochem Biophys Res Commun 1987;149:1186-92.
24. Urata H, Nishimura H, Ganten D. Chymase-dependent angiotensin II forming system in humans. Am J Hypertens 1996;9:277-84.
25. Schunkert H, Ingelfinger JR, Hirsh AT, Pinto Y, Jacob H, Dzau VJ. Feedback regulation of angiotensin converting enzyme activity and mRNA levels by angiotensin II. Circ Res 1993;72:312-8.
26. Inagami T, Guo DF, Kitami Y. Molecular biology of angiotensin II receptors: an overview. J Hypertens 1994;12 Suppl 10:S83-94.
27. de Gasparo M, Husain A, Alexander W, et al. Proposed update of angiotensin receptor nomenclature. Hypertension 1995;25:924-7.
28. 2 receptors in the developing rat fetus. J Clin Invest 1991;88:921-33.
29. 2 angiotensin II receptor subtypes in the rat brain during development. Proc Natl Acad Sci USA 1991;88:11440-4.
30. 2 angiotensin II receptors in rat anterior cerebral arteries. Am J Physiol 1991;261:H667-70.
31. 2) in rat brain. Am J Physiol 1991;261:R209-16.
32. Viswanathan M, Tsutsumi K, Correa FM, Saavedra JM. Changes in expression of angiotensin receptor subtypes in the rat aorta during development. Biochem Biophys Res Commun 1991;179:1361-7.
33. Janiak P, Pillon A, Prost JF, Vilaine JP. Role of angiotensin subtype 2 receptor in neointima formation after vascular injury. Hypertension 1992;20:737-45.
34. Kambayashi Y, Bardham S, Inagami T. Peptide growth factors markedly decrease the ligand binding of angiotensin II type 2 receptor in rat cultured vascular smooth muscle cells. Biochem Biophys Res Commun 1993;194:478-82.
35. Rogers TB, Lokuta AJ. Angiotensin II signal transduction pathways in the cardiovascular system. Trends Cardiovasc Med 1994;4:110-6.
36. Berridge MJ. Inositol trisphosphate and diacylglycerol: two interacting second messengers. Annu Rev Biochem 1987;56:159-83.
37. Rasmussen H, Takuwa Y, Park S. Protein kinase C in the regulation of smooth muscle contraction. FASEB J 1987;1:177-85.
38. Farago A, Nishizuka Y. Protein kinase C in transmembrane signalling. FEBS Lett 1990;268:350-4.
39. 2+ mobilization and protein kinase C activation. J Biol Chem 1989;264:526-30.
40. Molloy CJ, Taylor DS, Weber H. Angiotensin II stimulation of rapid protein tyrosine phosphorylation and protein kinase activation in rat aortic smooth muscle cells. J Biol Chem 1993;268:7338-45.
41. Davis RJ. The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 1993;268:14553-6.
42. + exchange and intracellular pH. J Biol Chem 1990;265:19632-7.
43. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1419-24.
44. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia. J Clin Invest 1992;90:456-61.
45. Stoffer GA, Owens GK. Angiotensin II induced mitogenesis of spontaneously hypertensive rat derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor-beta. Circ Res 1992;70:820-8.
46. Ito H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cells growth response to angiotensin II. J Clin Invest 1993;91:2268-74.
47. Koibuchi Y, Lee WS, Gibbons GH, Pratt RE. Role of transforming growth factor β-1 in the cellular growth response to angiotensin II. Hypertension 1993;21:1046-50.
48. Owens GK. Determinants of angiotensin II induced hypertrophy versus hyperplasia in vascular smooth muscle. Drug Dev Res 1993;29:83-7.
49. Geisterfer AT, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988;62:749-56.
50. + exchange. J Clin Invest 1989;83:822-9.
51. Resink TJ, Scott-Burden T, Baur U, Bühler FR. Increased proliferation rate and phosphoinositide turnover in cultured smooth muscle cells from spontaneously hypertensive rats. J Hypertens 1987;5:S145-8.
52. Paquet J-L, Baudouin-Legros M, Brunelle G, Meyer P. Angiotensin II induced proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens 1990;8:565-72.
53. Korsgaard N, Mulvany MJ. Cellular hypertrophy in mesenteric resistance vessels from renal hypertensive rats. Hypertension 1998;12:162-7.
54. Mulvany MJ. Control of vascular structure. Am J Med 1993;94 Suppl 4A:S20-3.
55. Mulvany MJ, Baandrup U, Gundersen HJG Evidence for hyperplasia in mesenteric resistance vessels of spontaneously hypertensive rats using a 3-dimensional dissector. Circ Res. 57:1985;794-800.
56. Korsgaard N, Aalkjaer C, Heagerty AM, Izzard A, Mulvany MJ. Histology of subcutaneous small arteries from patients with hypertension. Hypertension 1993;22:523-6.
57. Thybo NK, Korsgaard N, Mulvany MJ. Morphology and function of mesenteric resistance arteries in transgenic rats with low renin hypertension. J Hypertens 1992;10:1191-6.
58. Baumbach G, Heistad DD. Remodeling of cerebral arterioles in chronic hypertension. Hypertension 1989;13:968-72.
59. Gibbons GH, Pratt RE, Dzau VJ Angiotensin II is a bifunctional vascular smooth muscle cell growth factor [abstract]. Hypertension. 14:1989;358.
60. Udenfriend S, Cardinale G, Spector S. Hypertension induced vascular fibrosis and its reversal by antihypertensive drugs. In: Laragh JH, Bühler FR, Seldin OW, editors. Frontiers in Hypertension Research. New York: Springer-Verlag, 1981:404-11.
61. Hahn AW, Kern F, Bühler FR, Resink TJ The renin angiotensin system and extracellular matrix. Clin Invest. 71(Suppl 5):1993;S7-S12.
62. Kawahara Y, Sunako M, Tsuda T, Fukuzaki H, Fukumoto Y, Takai Y. Angiotensin II induces expression of the c-fos gene through protein kinase C activation and calcium ion mobilization in cultured vascular smooth muscle cells. Biochem Biophys Res Commun 1988;150:52-9.
63. Naftilan AL, Pratt RE, Eldridge CS, Lin HL, Dzau VJ. Angiotensin II induces c-fos expression in smooth muscle via transcriptional control. Hypertension 1989;13:706-11.
64. Naftilan AJ, Gilliland GK, Eldridge CS, Kraft AS. Induction of the proto-oncogene c-jun by angiotensin II. Mol Cell Biol 1990;10:5536-40.
65. Takeuchi K, Nakamura N, Cook NS, Pratt RE, Dzau VJ. Angiotensin II can regulate gene expression by the AP-1 binding sequence via a protein kinase C-dependent pathway. Biochem Biophys Res Commun 1990;172:1189-94.
66. Tsuda T, Alexander RW. Angiotensin II stimulates phosphorylation of nuclear lamins via a protein kinase C-dependent mechanism in cultured vascular smooth muscle cells. J Biol Chem 1990;265:1165-70.
67. Koh E, Morimoto S, Tomita J, et al. Effects of an angiotensin II receptor antagonist, CV-1194, on angiotensin II-induced increases in cytosolic free calcium concentration, hyperplasia and hypertrophy of cultured vascular smooth muscle cells. J Cardiovasc Pharmacol 1994;23:175-9.
68. Hahn AW, Jonas U, Bühler FR, Resink TJ. Activation of human peripheral monocytes by angiotensin II. FEBS Lett 1994;347:178-80.
69. Van Leeuwen RTJ, Kol A, Andreotti F, Kluft C, Maseri A, Sperti G. Angiotensin II increases plasminogen inhibitor type 1 and tissue type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994;90:362-8.
70. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin angiotensin system and fibrinolytic function. Circulation 1993;87:1969-73.
71. Brunner HR, Laragh JH, Baer L, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972;286:441-9.
72. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991;324:1098-104.
73. Lever AF. Slow pressor mechanisms in hypertension: a role for hypertrophy of resistance vessels? J Hypertens 1986;4:515-24.
74. Folkow B "Structural factor" in primary and secondary hypertension. Hypertension. 16:1990;89-101.
75. Kato H, Suzuki H, Ogata Y, Tominaga T, Sato A, Saruta T Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J Hypertens. 9:1991;17-22.
76. Katz AM. Angiotensin II: hemodynamic regulator or growth factor? J Mol Cell Cardiol 1990;22:739-47.
77. Levy BI, Michel J-B, Salzmann J-L, et al. Arterial effects of angiotensin-converting enzyme inhibition in renovascular and spontaneously hypertensive rats. J Hypertens 1988;6 Suppl 3:S23-5.
78. Levy BI, Michel J-B, Salzmann J-L, et al. Effects of chronic inhibition of converting enzyme on mechanical and structural properties of arteries in rat renovascular hypertension. Circ Res 1988;63:227-39.
79. Lee RMKW, Berecek KH, Tsoporis J, McKenzie R, Triggle CR. Prevention of hypertension and vascular changes by captopril treatment. Hypertension 1991;17:141-50.
80. Levy BI, Safar ME. Remodelling of the vascular system in response to hypertension and drug therapy. Clin Exp Pharmacol Physiol 1992;S19:33-7.
81. Sen S, Smeby RR, Bumpus FM. Renin in rats with spontaneous hypertension. Circ Res 1972;31:876-80.
82. Shiono K, Sokabe H. Renin-angiotensin system in spontaneously hypertensive rat. Am J Physiol 1976;231:1295-9.
83. Clozel J-P, Kuhn H, Hefti F. Vascular protection with cilazopril in hypertension. J Cardiovasc Pharmacol 1992;19 Suppl 5:S28-33.
84. Sen S, Tarazi RC, Khairallah PA, Bumpus FM. Cardiac hypertrophy in spontaneously hypertensive rats. Circ Res 1974;35:775-81.
85. Tsoporis J, Leenen FHH. Effects of hydralazine on blood pressure, pressor mechanisms, and cardiac hypertrophy in two-kidney, one-clip hypertensive rats. Can J Physiol Pharmacol 1986;64:1528-34.
86. Kohlmann O, Bresnahan M, Gavras H Central and peripheral indices of sympathetic activity after blood pressure lowering with enalapril (MK-421) or hydralazine in normotensive rats. Hypertension. 6(Suppl I:I):1984;1-6.
87. Smeda JS, Lee RM, Forrest JB. Prenatal and postnatal hydralazine treatment does not prevent renal vessel wall thickening in SHR despite the absence of hypertension. Circ Res 1988;63:534-42.
88. Owens GK. Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats. Hypertension 1987;9:178-87.
89. Hajdu MA, Heistad DD, Ghoneim S, Baumbach GL Effects of antihypertensive treatment on composition of cerebral arterioles. Hypertension. 18(Suppl II:II):1991;15-21.
90. Christensen KL, Jespersen LT, Mulvany MJ Development of blood pressure in spontaneously hypertensive rats after withdrawal of long term treatment related to vascular structure. J Hypertens. 7:1989;83-90.
91. Frohlich ED, Horinaka S Cardiac and aortic effects of angiotensin converting enzyme inhibitors. Hypertension. 18(Suppl II:II):1991;2-7.
92. Van Belle E, Bauters C, Wernert N, et al. Angiotensin converting enzyme inhibition prevents proto-oncogene expression in the vascular wall after injury. J Hypertens 1995;13:105-12.
93. Linz W, Wiemer G, Scholkens BA. Contribution of bradykinin to the cardiovascular effects of ramipril. J Cardiovasc Pharmacol 1993;22 Suppl 9:S1-8.
94. Schiffrin EL, Deng LY, Larochelle P. Progressive improvement in the structure of resistance arteries in hypertensive patients after 2 years of treatment with an angiotensin I converting enzyme inhibitor. Am J Hypertens 1995;8:229-36.
95. Thybo NK, Stephens N, Cooper A, Aalkjaer C, Heagerty AM, Mulvany MJ. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995;25:474-81.
96. Ventura HO, Messerli FH, Oigman W. Impaired arterial compliance in borderline hypertension. Am Heart J 1984;108:132-7.
97. Simon AC, Levenson J, Maarek BC, Bouthier JD. Hemodynamic basis of early modifications of the large arteries in borderline hypertension. J Hypertens 1987;5:179-84.
98. Simon AC, Safar ME, Levenson JA, London GM, Levy BI, Chau NP. An evaluation of large arteries compliance in man. Am J Physiol 1979;237:H550-4.
99. Simon AC, Safar ME, Kheder AM, Levenson JA, London GM, Weiss YA. Systolic hypertension, hemodynamic mechanisms and choice fo antihypertensive treatment. Am J Cardiol 1979;44:505-11.
100. Messerli FH, Ventura H, Aristimuno GG, Suarez DH, Dreslinski GR, Frohlich ED. Arterial compliance in systolic hypertension. Clin Exp Hypertens 1982;4:1037-44.
101. Safar ME, Bouthier JA, Levenson JA, Simon AC. Peripheral large arteries and the response to antihypertensive treatment. Hypertension 1993;5 Suppl III:III-63-8.
102. Simon AC, Levenson JA, Bouthier JD, et al. Comparison of oral MK-421 and propranolol in mild to moderate essential hypertension and their effects on arterial and venous vessels of the forearm. Am J Cardiol 1984;53:781-5.
103. Simon AC, Levenson JA, Bouthier JD, Maarek BC, Safar ME. Effects of acute and chronic angiotensin converting enzyme inhibition on large arteries in human hypertension. J Cardiovasc Pharmacol 1985;7 Suppl 1:S45-51.
104. Levenson J, Le Quan Sang KH, Devynck MA, Gitel R, Simon A. The role of antihypertensive drugs in counteracting adverse influences on large arteries. Am Heart J 1987;114:992-7.
105. Asmar RG, Pannier B, Santoni JP, et al. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 1988;78:941-50.
106. Safar ME, Levy BI The effect of hypertension and ACE inhibition on arterial structure and compliance. Clin Exp Pharmacol Physiol. 19(Suppl 19):1992;29-32.
107. Simon AC, Levenson J, Chau NP, Pithos-Merli I. Role of arterial compliance in the physiopharmacological approach to human hypertension. J Cardiovasc Pharmacol 1992;19 Suppl 5:S11-20.
108. Kool MJ, Lustermans FA, Breed JG, et al. The influence of perindopril and the diuretic combination of amiloride + hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients. J Hypertens 1995;13:839-48.
109. Levenson JA, Simon AC, Safar ME, Bouthier JD, Maarek BC. Large arteries in hypertension: acute effect of a new calcium entry blocker, nitrendipine. J Cardiovasc Pharmacol 1984;6 Suppl 7:S1006-10.
110. Levenson JA, Simon AC, Bouthier JD, Maarek BC, Safar ME. The effect of acute and chronic nicardipine therapy on forearm arterial hemodynamics in essential hypertension. Br J Clin Pharmacol 1985;20 Suppl:S107-13.
111. Levenson JA, Simon AC, Bouthier JD, Benetos AM, Safar ME Postsynaptic alpha blockade and brachial artery compliance in essential hypertension. J Hypertens. 2:1984;37-41.
112. Chau NP, Pithois-Merli I, Levenson J, Simon A. Comparative haemodynamic effects of ketanserin and ritanserin in the proximal and distal upper limb circulations of hypertensive patients. Eur J Clin Pharmacol 1989;37:315-20.
113. Achimastos A, Girerd X, Simon AC, Pithois-Merli I, Levenson J. The efficacy of a transdermal formulation of clonidine in mild to moderate hypertension and its effects on the arterial and venous vasculature of the forearm. Eur J Clin Pharmacol 1987;33:111-4.
114. Perret F, Mooser V, Hayos Det al. Evaluation of arterial compliance. Effects of antihypertensive drugs. Hypertension. 18(Suppl II:II):1991;77-83.
115. Hayoz D, Nussberger J, Waeber B, Brunner HR. The renin-angiotensin system and arterial wall behaviour. J Cardiovasc Pharmacol 1993;22 Suppl 5:S48-52.
116. Folkow B, Hansson L, Sivertsson R. Structural vascular factors in the pathogenesis of hypertension. In: Robertson, editor. Handbook of Hypertension: Clinical Aspects of Essential Hypertension. Amsterdam: Elsevier, 1983;133-50.
117. Svensson A, Gudbrandsson T, Sivertsson R, Hansson L. Hemodynamic effects of metoprolol and pindolol: a comparison in hypertensive patients. Br J Clin Pharmacol 1982;13:S259-67.
118. Gretzer I, Dunér H, Lagerbäck B. Haemodynamic effects of pindolol in essential hypertension with special reference to resistance vessels in the forearm during maximal vasodilatation. J Hypertens 1985;3 Suppl 3:S215-7.
119. Agabiti-Rosei E, Muiesan ML, Geri A, et al. Long-term antihypertensive treatment may induce normalization of left ventricular mass before complete regression of vascular structural changes: consequences for cardiac function at rest and during stress. J Hypertens 1988;6 Suppl 4:S94-6.
120. Dahlöf B, Hansson L. The influence of antihypertensive therapy on the structural arteriolar changes in essential hypertension: different effects of enalapril and hydrochlorothiazide. J Intern Med 1993;234:271-9.
121. Ludwig M, Stumpe KO, Heagerty AM, et al. Vascular wall thickness in hypertension: the Perindopril Regression Vascular Thickening European Community Trial (PROTECT). J Hypertens 1993;11 Suppl 5:S316-7.
122. The PHYLLIS Project Group. Plaque Hypertension Lipid-Lowering Italian Study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolemic hypertensive subjects. J Hypertens 1993;11 Suppl 5:S314-5.
123. Chiu AT, Roscoe WA, McCall DE, Timmermans PB. Angiotensin II-1 receptors mediate both vasconstrictor and hypertrophic responses in rat aortic smooth muscle cells. Receptor 1991;1:133-40.
124. Millet D, Desgranges C, Campan M, Gadeau AP, Costerousse O. Effects of angiotensins on cellular hypertrophy and c-fos expression in cultured arterial smooth muscle cells. Eur J Biochem 1992;206:367-72.
125. Sachinidis A, Ko Y, Weisser P, et al. EXP31754, a metabolite of losartan (MK 954, DuP 753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells. J Hypertens 1993;11:155-62.
126. 1 receptor. J Hypertens 1992;10:1463-9.
127. Ko Y, Gor A, Appenheimer M, et al. Losartan inhibits the angiotensin II-induced stimulation of the phosphoinositide signalling system in vascular smooth muscle cells. Eur J Pharmacol 1992;227:215-9.
128. Oddie CJ, Dilley RJ, Kanellakis P, Bobik A. Chronic angiotensin II type 1 receptor antagonism in genetic hypertension: effects on vascular structure and reactivity. J Hypertens 1993;11:717-24.
129. Soltis EE. Alterations in vascular structure and function after short-term losartan treatment in spontaneously hypertensive rats. J Pharmacol Exp Ther 1993;266:642-6.
130. Morton JJ, Beattie EC, MacPherson F. Angiotensin II receptor antagonist losartan has persistent effects on blood pressure in the young spontaneously hypertensive rat: lack of relation to vascular structure. J Vasc Res 1992;29:264-9.
131. Morishita R, Gibbons GH, Ellison EK, et al. Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme. J Clin Invest 1994;94:978-84.